| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -46,062 |
| Stock-based compensation expense | 4,739 |
| Realized gain on investments | 0 |
| Non-cash lease expense | 86 |
| Prepaid expenses and other current assets | -670 |
| Other non-current assets | -618 |
| Operating lease liabilities | -99 |
| Accrued expenses and other current liabilities | 1,687 |
| Accounts payable | -609 |
| Depreciation on property and equipment | 24 |
| Accretion of discount on investments | 2,997 |
| Net cash used in operating activities | -41,943 |
| Maturities of investments | 167,878 |
| Purchases of property and equipment | 16 |
| Purchases of investments | 125,618 |
| Net cash provided by (used in) investing activities | 42,244 |
| Proceeds from exercise of stock options | 623 |
| Proceeds from public offering of common stock, net of issuance costs | 0 |
| Repurchase of common stock originally issued upon early exercise of stock options | 7 |
| Net cash provided by financing activities | 616 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 917 |
Tourmaline Bio, Inc. (TRML)
Tourmaline Bio, Inc. (TRML)